Moonlake Immunotherapeutics AG
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Public, Subsidiary
- Established
- 2021-03-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.moonlaketx.com
Clinical Trials
17
Active:9
Completed:2
Trial Phases
3 Phases
Phase 1:8
Phase 2:2
Phase 3:7
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (17 trials with phase data)• Click on a phase to view related trials
Phase 1
8 (47.1%)Phase 3
7 (41.2%)Phase 2
2 (11.8%)A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- MoonLake Immunotherapeutics AG
- Target Recruit Count
- 835
- Registration Number
- NCT07007637
- Locations
- 🇺🇸
Clinical Site, Birmingham, Alabama, United States
An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector
- First Posted Date
- 2025-05-29
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- MoonLake Immunotherapeutics AG
- Target Recruit Count
- 120
- Registration Number
- NCT06994936
- Locations
- 🇬🇧
Clinical Site, London, United Kingdom
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
- First Posted Date
- 2025-01-10
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- MoonLake Immunotherapeutics AG
- Target Recruit Count
- 35
- Registration Number
- NCT06768671
- Locations
- 🇺🇸
Clinical Site, Norfolk, Virginia, United States
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- MoonLake Immunotherapeutics AG
- Target Recruit Count
- 960
- Registration Number
- NCT06641076
- Locations
- 🇺🇸
Clinical Site, Beckley, West Virginia, United States
Evaluation of Sonelokimab in Patients with Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
Phase 3
Recruiting
- Conditions
- Arthritis, Psoriatic
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- MoonLake Immunotherapeutics AG
- Target Recruit Count
- 600
- Registration Number
- NCT06641089
- Locations
- 🇺🇸
Clinical Site, Lubbock, Texas, United States
- Prev
- 1
- 2
- Next
News
No news found